Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...

Full description

Bibliographic Details
Main Authors: Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc R. Matrana, Simon J. Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Diagnostics
Subjects:
body mass index
cabozantinib
obesity
prognosis
real-world data
renal cell carcinoma
Online Access:https://www.mdpi.com/2075-4418/11/1/138

Internet

https://www.mdpi.com/2075-4418/11/1/138

Similar Items